The Library
A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update
Tools
Biswas, S., Wrigley, J., East, C., Hern, A., Marshall, A. (Andrea), Dunn, Janet A., Lorigan, P., Middleton, M. (Mark) and Corrie, P. (2008) A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update. ecancermedicalscience, Vol.2 . p. 108. doi:10.3332/ecancer.2008.108 ISSN 1754-6605.
|
Text
WRAP_Marshall_can-2-108.pdf - Published Version Download (927Kb) | Preview |
Official URL: http://dx.doi.org/10.3332/ecancer.2008.108
Abstract
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of developing metastasis and subsequent disease-related death. Given this, it is important that novel therapies are investigated in the adjuvant melanoma setting. Since angiogenesis is essential for primary tumour growth and the development of metastasis, anti-angiogenic agents are attractive potential therapeutic candidates for clinical trials in the adjuvant setting. Therefore, we initiated a phase II trial in resected high-risk cutaneous melanoma, assessing the efficacy of bevacizumab versus observation.
In the interim safety data analysis, we demonstrate that bevacizumab is a safe therapy in the adjuvant melanoma setting with no apparent increase in the surgical complication rate after either primary tumour resection and/or loco-regional lymphadenectomy.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Library of Congress Subject Headings (LCSH): | Melanoma -- Treatment, Neovascularization inhibitors, Bevacizumab | ||||
Journal or Publication Title: | ecancermedicalscience | ||||
Publisher: | The European Institute of Oncology | ||||
ISSN: | 1754-6605 | ||||
Official Date: | 12 November 2008 | ||||
Dates: |
|
||||
Volume: | Vol.2 | ||||
Page Range: | p. 108 | ||||
DOI: | 10.3332/ecancer.2008.108 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Open Access (Creative Commons) | ||||
Date of first compliant deposit: | 1 August 2016 | ||||
Date of first compliant Open Access: | 1 August 2016 |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year